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Abstract
We utilized a system for sequence-specific RNA base editing via Adenosine Deaminases acting on 
RNA (ADAR) enzymes with associated ADAR guide RNAs (adRNAs). We systematically 
engineered it to harness ADARs, and comprehensively evaluated its specificity and activity in vitro 
and in vivo via two mouse models of human disease. We anticipate this platform will enable 
tunable and reversible engineering of RNAs for diverse applications.
Adenosine to inosine RNA editing, a common post-transcriptional RNA modification, is 
catalyzed by Adenosine Deaminases acting on RNA (ADAR) enzymes1. Inosine is a 
deaminated form of adenosine that is biochemically recognized as guanine. Recently, 
multiple studies have demonstrated ADAR mediated targeted RNA editing2–9. Building on 
these, we engineered here two orthogonal toolsets for sequence-specific programmable RNA 
base editing in vitro and in vivo. Specifically, we utilized a system for targeted RNA editing 
via ADAR1/2 with associated ADAR guide RNAs (adRNAs) (Figure 1a). The adRNAs 
comprise in part a programmable antisense region that is complementary to the target RNA 
sequence with a mismatched cytidine opposite the target adenosine. Additionally, they bear 
in one version, zero, one, or two ADAR-recruiting domains engineered from the naturally 
occurring ADAR substrate GluR2 pre-mRNA3,4 (referred hereon as GluR2 adRNA); and in 
a second format, two MS2 hairpins flanking the antisense region (referred hereon as MS2 
adRNA). The GluR2 adRNA was systematically optimized to enhance recruitment of 
exogenous and/or endogenous ADARs by evaluating multiple scaffold variants, including 
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mutagenized scaffolds based on G-C versus A-U pairing, addition of editing inducer 
elements10, and antisense domain length11 and mis-match position modifications 
(Supplementary Figures 1, 2a–c). The latter MS2 adRNA version was in turn optimized to 
harness synthetic proteins comprising the deaminase domains (DD) of ADAR1 or ADAR2 
fused to the MS2 Coat Protein (MCP), via systematic antisense domain length and mis-
match position modifications, coupled with use of hyper-active versions of the deaminase 
domains, and versions bearing nuclear localization (NLS) versus export (NES) signals 
(Figure 1b, Supplementary Figures 3a, 3b).
We comprehensively evaluated the activity of the above two systems and also benchmarked 
it with the recently developed RNA editing system based on Cas13b7. Via these in vitro 
experiments we observed: 1) the engineered constructs were active in their ability to effect 
targeted RNA editing with yields comparable to the Cas13b based system (Figure 1b, 
Supplementary Figure 4a, Supplementary Tables 1, 2), and U6 transcribed adRNAs and 
chemically synthesized adRNAs were both effective formats (Supplementary Figure 4b); 2) 
adRNAs bearing long antisense domains, both with and without GluR2 domains, suffice to 
recruit exogenously expressed ADARs, and to a degree endogenous ADARs12 too to enable 
efficient RNA editing (Figure 1b, Supplementary Figures 2b, 2c, 4c); 3) the constructs based 
on the MS2 adRNAs and corresponding MCP-ADAR1/2 fusions showed the highest and 
most robust activity, including across a large panel of endogenous genes chosen across a 
spectrum of different expression levels (Figure 1b, Supplementary Figure 4c); 4) use of a 
NES and/or hyper-active deaminase domains in the MCP-ADAR1/2 fusions consistently 
yielded higher RNA editing yields at the target adenosine, but also led to a higher propensity 
of editing at non-targeted adenosines in the flanking sequences (Figure 1b, Supplementary 
Figure 5a). To further validate this, we showed that a similar promiscuity ensued also from 
deletion of the native NLS domain in ADAR2 (∆1–138)13 (Supplementary Figures 5b–d); 
and 5) these two toolsets we operationally orthogonal: specifically, we evaluated the editing 
efficiency of the MCP-ADAR2 deaminase domain fusion with a co-expressed MS2 adRNA 
or GluR2 adRNA and observed on-target editing only via the former. Conversely, we also 
confirmed that full-length ADAR2 was recruited by the GluR2 adRNA and not the MS2 
adRNAs (Supplementary Figure 3b).
Having demonstrated robust activity of this toolset, we next investigated its specificity 
profiles via analysis of the transcriptome-wide off-target A->G editing effected by this 
system (Figure 1c). To this end, HEK 293T cells were transfected with each construct and 
analyzed by RNA-seq. Untransfected cells were included as controls. From each sample, we 
collected ~40 million uniquely aligned sequencing reads. We then used Fisher’s exact test to 
quantify significant changes in A->G editing yields, relative to untransfected cells, at each 
reference adenosine site having sufficient read coverage. The number of sites with at least 
one A->G editing event detected in any of the samples was computed. Of these, the number 
of sites with statistically significant A->G edits, at a false discovery rate (FDR) of 1%, and 
with fold change of at least 1.1, was found to vary over a wide range, from lowest for the 
MCP-ADAR2 DD-NLS construct, to highest for the MCP-ADAR1 DD (E1008Q)-NES 
(Supplementary Figures 6–9, Supplementary Tables 3, 4). To investigate the distribution of 
editing yields, we generated violin plots considering the A-sites whose editing yields 
changed significantly in at least one sample (Figure 1). Taken together, our RNA-seq 
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experiments revealed that transcriptome-wide off-target edits were: 1) less prevalent in 
MCP-ADAR constructs with NLS than constructs with NES; 2) less prevalent in MCP-
ADAR2 constructs than MCP-ADAR1 constructs; 3) less prevalent in the wild-type MCP-
ADAR constructs than the E>Q hyperactive mutants (Supplementary Figure 10a, 
Supplementary Table 4); and 4) the off-targets were primarily due to ADAR overexpression 
and use of adRNAs alone resulted in least number of off-targets (Supplementary Figure 
10b).
Following these in vitro studies, we next evaluated our system in in vivo RNA targeting for 
gene therapy applications, utilizing the adRNA cum exogenous ADAR expression construct 
versions, as those consistently enabled the highest in vitro RNA editing yields. We focused 
first on the mdx mouse model for Duchenne muscular dystrophy (DMD) which bears an 
ochre stop site in exon 23 of the dystrophin gene. This choice was additionally motivated by 
the fact that nonsense mutations in general are responsible for nearly 11% of all described 
gene lesions causing inheritable human disease, and close to 20% of disease-associated 
single base substitutions that affect the coding regions of genes14. Thus, validation of an 
RNA editing strategy here would have broad therapeutic application. Towards this, we first 
optimized RNA editing of stop codons in vitro (Supplementary Figure 11). Notably, we 
observed that addition of a second copy of the adRNA significantly improved the targeting 
efficiencies (Supplementary Figure 11c), and thus in all our in vivo studies we utilized a 
dual-adRNA delivery approach. We next packaged our constructs into AAV8, and injected 
2E+12 vector genomes (vg)/muscle into the tibialis anterior (TA) or gastrocnemius of mdx 
mice. To further benchmark our approach, we concurrently also targeted the mdx mice via 
CRISPR-Cas9 based excision of exon 2315–17 (Figure 2a). Four or eight weeks post 
injection, TA and gastrocnemius muscles were collected from mdx mice, wild type mice, 
mice treated with adRNA targeting and non-targeting controls, and CRISPR-Cas9. 
Immunofluorescence staining revealed clear restoration of dystrophin expression via 
targeted RNA editing (Figure 2b, Supplementary Figure 12a). In addition, nNOS activity 
was also restored at the sarcolemma (Figure 2b, Supplementary Figure 12a). RNA editing 
yields (TAA->TGG/TAG/TGA) of up to 3.6%, and TAA->TGG up to 2.4% were observed 
in treated mice (Figure 2c, Supplementary Figure 11e). Western blots of the treated muscles 
confirmed the immunofluorescence observations, demonstrating 1–2.5% protein restoration. 
(Supplementary Figures 12b). As benchmark, muscles injected with vectors bearing 
CRISPR-Cas9 also expectedly led to restoration of dystrophin expression in a subset of the 
muscle cells (Figure 2b), with Western blots of the treated muscles confirming up to 10% 
protein restoration. (Supplementary Figure 12c).
To further confirm the efficacy of this approach, we next evaluated ADAR mediated RNA 
editing in an independent mouse model of human disease, the male sparse fur ash (spfash) 
mouse model of ornithine transcarbamylase (OTC) deficiency. The spfash mice harbor a G-
>A point mutation in the last nucleotide of the fourth exon of the OTC gene, which leads to 
OTC mRNA deficiency and production of a mutant protein18. Recent studies have 
demonstrated the use of CRISPR-Cas9 and homologous recombination based strategies for 
robust correction of this mutation in neonatal mice19. To test the effectiveness of our system 
in editing the point mutation in spfash OTC mRNA (Figure 2d), we initially evaluated our 
constructs in vitro (Supplementary Figure 13a). We next packaged our constructs into 
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AAV8, which has high liver tropism19, and injected 2.5E+12 vg/mouse in 10–12 week old 
spfash mice. Three to four weeks post injection, we collected liver samples from spfash mice, 
wild-type litter mates, and spfash mice treated with the ADAR2 targeting and non-targeting 
vectors and evaluated corresponding editing efficiency via NGS. Notably, upon delivery of 
the adRNA and the ADAR2, we observed 0.8–4.7% edited mRNA amongst the correctly 
spliced OTC mRNA, and interestingly adRNA alone resulted in low but significant RNA 
editing yields (Figure 2e, refer Methods). Moreover, upon the delivery of the hyper-active 
ADAR2 mutant (E488Q), we observed a high edited fraction (4.6–33.8%) in the correctly 
spliced OTC mRNA (Figure 2e, Supplementary Figure 13b), 4.6–8.2% in the OTC pre-
mRNA (Supplementary Figure 13c), and confirmed a reduction in the incorrectly spliced 
product (Supplementary Figure 13d). Western blots of the treated liver samples confirmed 
partial (2.5–5%) restoration of OTC protein (Supplementary Figure 13e).
Taken together, our results establish the utility of RNA-guided ADARs for in vivo RNA 
editing of point mutations. Moving forward, we note that, sequence preferences of the 
ADAR enzymes, RNA folding, intrinsic half-life, localization, translation machinery9, and 
resident RNA binding proteins can potentially impact accessibility and editability of target 
sites in the RNA, and will be important design parameters to consider for enabling 
efficacious targeting. For instance, in the mdx model, ADAR based RNA editing approaches 
have to compete with nonsense mediated decay of mutant dystrophin mRNA, and also the 
requirement for effecting two A->I substitutions in the context of non-ideal flanking 
nucleotides to eliminate the premature stop codon and potential impact on RNA stability and 
function. Furthermore, in the spfash model, the need to target the transient OTC pre-mRNA 
entails rapid target engagement and editing. Further progress will also require addressing 
important limitations of the system such as the off-targets induced by intrinsic enzyme-RNA 
binding, processivity, promiscuity, stimulation of the interferon response by the delivery 
modalities themselves (such as lipid, nanoparticles or viral) leading in turn to increased 
endogenous ADAR expression, potential of adRNAs to induce RNAi, and also off-target 
hybridization of the antisense domain of the adRNA which could potentially have 
deleterious effects20. In this regard, our studies revealed toxicity in mice systemically 
injected with the hyperactive ADAR mutants (Supplementary Figure 14). While we 
hypothesize that off-target RNA editing due to the hyper-active version might be responsible 
for the negative impact on mouse health, additional work needs to be performed to ascertain 
underlying mechanisms. These studies will be critical to aid systematic improvement of the 
specificity and safety of this approach. Another important consideration while considering 
RNA targeting for gene therapy, especially via the use of non-integrating vectors, is the 
necessity for periodic re-administration of the effector constructs, owing to the typically 
limited half-life of edited mRNAs and effectors. In this regard, compared to the CRISPR 
based RNA editing approaches, the RNA-guided ADAR strategy is directly human 
therapeutics relevant, as versions of the same solely utilize effector RNAs and human 
proteins. Additionally, as ADARs are widely expressed, for instance, ADAR1 across most 
human tissues and ADAR2 in particular in the lung and brain, endogenous recruitment of 
these via adRNAs bearing long-antisense domains (as demonstrated in Figures 1, 2e and 
Supplementary Figures 2, 4) presents a very attractive strategy for efficacious RNA editing. 
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With progressive improvements, we thus anticipate this toolset will have broad implications 
for diverse basic science and therapeutic applications.
ONLINE METHODS
Vector design and construction
One or two copies of the adRNAs were cloned into an AAV vector containing a human U6 
and mouse U6 promoter along with a CMV promoter driving the expression of the enzyme. 
To construct the GFP reporters – GFP-Amber, GFP-Ochre and GFP-Opal, three gene blocks 
were synthesized with ‘TAG’, ‘TAA’ and ‘TGA’ respectively replacing the Y39 residue of 
the wild type GFP and were cloned downstream of a CAG promoter. To construct the OTC 
and DMD reporters, 200 bp fragments of the spfash OTC and mdx DMD transcript bearing 
the target adenosine(s) to be edited were cloned downstream of the CAG promoter.
Mammalian cell culture and transfection
All HEK 293T cells were grown in Dulbecco’s Modified Eagle Medium supplemented with 
10% FBS and 1% Antibiotic-Antimycotic (Thermo Fisher) in an incubator at 37 °C and 5% 
CO2 atmosphere. All in vitro transfection experiments were carried out in HEK 293T cells 
using the commercial transfection reagent Lipofectamine 2000 (Thermo Fisher). All in vitro 
RNA editing experiments involving a reporter were carried out in 24 well plates using 400ng 
of reporter plasmid and 800ng of the adRNA+enzyme plasmid. All in vitro RNA editing 
experiments targeting an endogenous transcript were carried out in 24 well plates using 
800ng of the adRNA/Enzyme plasmid. dCas13b-ADAR2DDE488Q based RNA editing 
experiments were carried out using 800ng of the enzyme plasmid (Addgene #103864) as 
well 800 ng of the gRNA plasmid. Cells were transfected at 25–30% confluence and 
harvested 60 hours post transfection for quantification of editing. Chemically synthesized 
adRNAs (synthesized via IDT or Synthego) were transfected using Lipofectamine 3000 
(Thermo Fisher) at an amount of 20 pmol/well.
Production of AAV vectors
AAV8 particles were produced using HEK 293T cells via the triple transfection method and 
purified via an iodixanol gradient. Confluency at transfection was about 80%. Two hours 
prior to transfection, DMEM supplemented with 10% FBS was added to the HEK 293T 
cells. Each virus was produced in 5 × 15 cm plates, where each plate was transfected with 
7.5 ug of pXR-8, 7.5 of ug recombinant transfer vector, 7.5 ug of pHelper vector using PEI 
(1ug/uL linear PEI in 1×DPBS pH 4.5, using HCl) at a PEI:DNA mass ratio of 4:1. The 
mixture was incubated for 10 minutes at RT and then applied dropwise onto the cell media. 
The virus was harvested after 72 hours and purified using an iodixanol density gradient 
ultracentrifugation method. The virus was then dialyzed with 1 × PBS (pH 7.2) 
supplemented with 50 mM NaCl and 0.0001% of Pluronic F68 (Thermo Fisher) using 
50kDA filters (Millipore), to a final volume of ~1 mL and quantified by qPCR using primers 
specific to the ITR region, against a standard (ATCC VR-1616).
AAV-ITR-F: 5’-CGGCCTCAGTGAGCGA-3’ and AAV-ITR-R: 5’-
GGAACCCCTAGTGATGGAGTT-3’.
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RNA isolation and Next Generation Sequencing library preparation
RNA from animal tissue was extracted using the RNeasy Plus Universal Mini Kit (Qiagen), 
according to the manufacturer’s protocol. RNA from cells was extracted using the RNeasy 
Mini Kit (Qiagen). cDNA was synthesized from 500ng RNA using the Protoscript II First 
Strand cDNA synthesis Kit (NEB). Next generation sequencing libraries were prepared as 
follows. Briefly, 1ul of cDNA prepared above was amplified by PCR with primers that 
amplify about 150 bp surrounding the sites of interest using KAPA Hifi HotStart PCR Mix 
(Kapa Biosystems). PCR products were purified (Qiagen PCR Purification Kit/ Gel 
Extraction Kit) to eliminate byproducts. Libraries were constructed with NEBNext 
Multiplex Oligos for Illumina kit (NEB). 10 ng of input DNA was amplified with indexing 
primers. Samples were then pooled and loaded on an Illumina Miseq (150bp single-end run) 
or Hiseq (100bp paired-end run). Data analysis was performed using CRISPResso (Pinello, 
L. et al. 2016). A minimum of 100,000 reads were analyzed for all in vivo experiments. 
RNA-seq libraries were prepared from 300ng of RNA, using the NEBNext Poly(A) mRNA 
magnetic isolation module and NEBNext Ultra RNA Library Prep Kit for Illumina. Samples 
were pooled and loaded on an Illumina Hiseq (100bp paired-end run).
Quantification of OTC mRNA editing yields in the spfash mice
The spfash mice bear three forms of OTC RNA: the pre-mRNA, the correctly spliced mRNA 
and an incorrectly spliced, elongated mRNA formed due to the use of a cryptic splice site 48 
base pairs into intron 418. Let the total number of the correctly spliced mRNA be X, 
incorrectly spliced variant be Y and the pre-mRNA be Z. Xe, Ye and Ze denote the A->G 
edited mRNA in the three forms. The mRNA editing yield ideally would be calculated as 
(Xe+Ye+Ze)/(X+Y+Z). However, since it is not possible to amplify the spliced and pre-
mRNA variants using the same primers, in Figure 2e, we report the fraction of edited 
transcripts in the correctly spliced mRNA (Xe/X) which will in turn be translated to produce 
the OTC protein. In addition, in Supplementary Figure 14c, we also report the fraction of 
edited transcripts in the pre-mRNA (Ze/Z). This fraction, upon correct splicing will 
contribute to formation of OTC protein. Finally, the incorrectly spliced mRNA results in the 
production of a protein elongated by 16 amino acids which is selectively degraded. We have 
not quantified the edited transcripts in this fraction of mRNA since these edited transcripts 
cannot be used to produce a functional protein. In Supplementary Figure 14d, bands 
corresponding to X and Y are shown.
Animal experiments
All animal procedures were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committee (IACUC) of the University of California, San 
Diego. All mice were acquired from Jackson labs. AAVs were injected into the 
gastrocnemius or TA muscle of mdx mice (C57BL/10ScSn-Dmdmdx/J) using 2E+12 vg/
muscle. AAVs were injected into spfash mice (B6EiC3Sn a/A-Otcspf-ash/J) via retro-orbital 
injections using 2.5E+12 vg/mouse. Mice that appeared to have a rough hair coat, moved 
slowly and appeared slightly hunched were termed as sick mice and euthanized.
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Harvested gastrocnemius or TA muscles were placed in molds containing OCT compound 
(VWR) and flash frozen in liquid nitrogen. 10 μm sections were cut onto pre-treated 
histological slides. Slides were fixed using 4% Paraformaldehyde. Dystrophin and nNOS 
were detected with rabbit polyclonal antibodies against the C-terminal domain of dystrophin 
(1:200, Abcam 15277) and N-terminal domain of nNOS (1:100, Immunostar 24431) 
respectively, followed by a donkey anti-rabbit Alexa 546 secondary antibody (1:400, 
Thermo Fisher).
Western Blots
Muscle biopsies from mdx mice and liver biopsies from spfash mice were fragmented in 
RIPA buffer (Sigma) with a proteinase inhibitor cocktail (Roche) and incubated for 1 hour 
on ice with intermittent vortexing. Samples were centrifuged at 15500×g for 30 min at 4°C 
and the supernatant was isolated and quantified with a Pierce Coomassie Plus (Bradford) 
assay kit (Thermo Fisher). Protein isolate was mixed with 4× Laemmli Loading buffer 
(Biorad) and 2-Mercaptoethanol (Biorad) and boiled at 100°C for 10 min. 100 μg total 
protein from muscle biopsies or 60 ug from liver biopsies was loaded into each well of a4–
15% Mini Protean TGX gel (Biorad) with Tris-Glycine-SDS buffer (Biorad) and 
electrophoresed for 60 min at 100 V. Protein from muscle biopsies was transferred to 
nitrocellulose membranes overnight at 34V while that from liver biopsies was transferred at 
65V for 1hour 30 minutes in a 1X tris-glycine transfer buffer containing 10% methanol and 
0.1% SDS at 4°C. The blot was blocked for 1 hour in 5% milk-TBST. Blots were probed 
with rabbit anti-dystrophin (1:200, Abcam 15277), rabbit anti-GAPDH (1:4000, Cell 
Signaling 2118S), rabbit anti-OTC (1:800, Abcam 203859) and mouse anti-ADAR2 (1:150, 
Santa Cruz Biotechnology 73409) overnight at 4°C in 5% milk-TBST. Blots were washed 
with TBST and then incubated with anti-rabbit or anti-mouse horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling) for 1 hour in 5% milk-TBST. After 
washing with TBST, blots were visualized using SuperSignal West Femto 
Chemiluminescent Substyeild (Thermo Fisher) and X-Ray films.
Statistics and Reproducibility
In vitro experiments: All in vitro experiments were carried out once with a minimum of 3 
independent replicates.
In vivo experiments: For the mdx mouse model, ADAR2 and MCP-ADAR1 (E1008Q) NLS 
based experiments were carried out twice. Both rounds of experiments yielded consistent 
RNA editing efficiencies, dystrophin immunofluorescence and dystrophin restoration as seen 
by western blots. ADAR2 (E488Q) and CRISPR-Cas9 based experiments were carried out 
once. For the spfash mouse model, all experiments were carried out twice, based on the 
availability of mice. RNA editing efficiencies of the OTC transcript, both the spliced and 
pre-mRNA were consistent in both rounds of experiments. RT-PCR and Western blots were 
carried out on all animals in experimental set 1.
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Quantification of RNA A->G editing
RNA-seq read alignment—RNA-seq read pairs with 100 bases per read mate were 
aligned to the GRCh38 reference genome using STAR aligner version 2.6.0c (Dobin A et al 
2013). The genome index was built using primary assembly annotations from GENCODE 
release 28 (GRCh38.p12). Default parameters were used to run STAR, except for the 
following relevant settings: readMapNumber=−1, alignSJoverhangMin=5, 
alignSJDBoverhangMin=1, alignEndsType=EndToEnd, outFilterMismatchNmax=10, 
outFilterMultimapNmax=1, outSAMunmapped=None, outSAMmultNmax=1. The reads of 
the resulting uniquely aligned pairs were sorted by genomic coordinate using samtools sort 
(Li H. et al 2009). Duplicated read pairs were marked using samtools markdup and were 
removed from subsequent analysis. Tallies of total, aligned, duplicated, and remaining reads 
(not pairs) are reported for each sample in Supplementary Table 3.
Selection of reference sites for quantification of editing yields—The assessment 
of sites with significant changes in A-to-G editing yields (see below) is sensitive to the 
number of uniquely aligned reads available for each sample. To minimize potential biases 
when comparing different samples in terms of significantly edited sites, the uniquely aligned 
reads for each HEK293T sample were down-sampled using samtools view with option -s 
and the down-sampling fractions reported in Supplementary Table 3. These fractions were 
calculated by dividing the smallest number of uniquely aligned reads among all samples by 
the number of uniquely aligned reads available for the sample being down-sampled. Down-
sampling was not performed on the reads of the control sample, the first in Supplementary 
Table 3. The down-sampled reads where then processed using samtools mpileup. The output 
of this tool was parsed to extract the counts of each base found in the aligned reads at each 
A-site and T-site in the GRCh38 reference genome sequence. Insertions and deletions were 
ignored. Reference sites with read coverage less than 10 were omitted from downstream 
analysis. The number of remaining reference A- and T-sites with read coverage of at least 10 
varied by ~15% across the samples listed in Supplementary Table 3. Without down-
sampling, such number was found to vary by ~50%. From the reference A- and T-sites with 
read coverage of at least 10, a final list of total sites (A-sites and T-sites) was selected by 
choosing those sites that were common to all samples and for which at least one G or C was 
observed at a reference A- or T-site, respectively, in the aligned reads of at least one sample. 
The other sites, those not common to all samples or with zero observed editing events in all 
samples, were discarded.
Assessment of significant changes in A-to-G editing yields—To uncover 
significant changes in A-to-G editing yields, several pairs of control and treatment samples 
were considered. For each pair, the control sample was the first sample listed in in 
Supplementary Table 3, while the treatment sample was one of the samples shown in Figure 
1. For each pair of compared samples, and for each reference A-site selected as described 
above, a Fisher exact test was carried out using a 2×2 contingency matrix C with entries 
defined as follows: C1,1 = count of bases other than G observed in the control sample, C2,1 = 
count of G bases observed in the control sample, C1,2 = count of bases other than G 
observed in the test sample, C2,2 = count of G bases observed in the test sample. A similar 
contigency matrix was used for each selected reference T-site, except that G was replaced 
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with C in the above definitions. The p-values calculated for all selected reference sites and 
for a given comparison of samples were adjusted for multiple testing using the Benjamini-
Hochberg method. A-sites and T-sites with adjusted p-values less than a false discovery rate 
(FDR) of 1% and with a fold change of at least 1.1 in editing yield were deemed to have a 
significant change in A-to-G editing yield on forward and reverse transcripts, respectively. 
The counts of these sites for each comparison of samples are shown as Nsig in 
Supplementary Figures 6–10, and are reported under the column “changed sites” in 
Supplementary Table 4. The total number of reference sites with a significant change in A-
to-G editing yield was computed. The editing yields at these sites were used to construct the 
distributions shown in Figure 1. The on-target A-to-G editing yields shown as blue circles in 
Figure 1 and Supplementary Figures 6–10 were estimated for each sample as C2,2 / (C1,2 + 
C2,2) using counts observed at the intended target A-site in the RAB7A transcript. These 
values are reported under the column “editing yield” in Supplementary Table 4. The 1-based 
genomic coordinate of the intended target A-site was found to be chr3:128814202 by 
submitting the following sequence to BLAT after selecting reference assembly hg38:
AGCGGCAGTATTCTGTACAGTAGACACAAGAATTATGTACGCCTTTTATCA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: Engineering programmable RNA editing and characterizing specificity profiles:
(a) Schematics of RNA editing via constructs utilizing the full length ADAR2 and an 
engineered adRNA derived from the GluR2 transcript, or MS2 Coat Protein (MCP) fusions 
to the ADAR1/2 deaminase domains and the corresponding MS2 hairpin bearing adRNA. 
(b) Comparison of RNA editing efficiency of the endogenous RAB7A transcript by different 
RNA editing constructs quantified by Sanger sequencing (efficiency calculated as a ratio of 
Sanger peak heights G/(A+G)). Experiments were carried out in HEK 293T cells. Values 
represent mean +/− SEM (n=3). (c) Violin plots representing distributions of A->G editing 
yields observed at reference sites where at least one treatment sample was found to have a 
significant change (Fisher’s exact test, FDR = 1%) in editing yield relative to the control 
sample. Blue circles indicate editing yields at the target A-site within the RAB7A transcript. 
Black dots represent median off-target editing yields. To better visualize the shapes of the 
distributions, their maximum extent along the y-axis was equalized across all plots, and were 
truncated at 60% yield.
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Figure 2: In vivo RNA editing in mouse models of human disease:
(a) Schematic of the DNA and RNA targeting approaches to restore dystrophin expression in 
the mdx mouse model of Duchenne Muscular Dystrophy: (i) a dual gRNA-CRISPR based 
approach leading to in frame excision of exon 23 and (ii) ADAR2 and MCP-ADAR1 based 
editing of the ochre codon. (b) Immunofluorescence staining for dystrophin in the TA 
muscle shows partial restoration of expression in treated samples (intra-muscular injections 
of AAV8-ADAR2, AAV8-ADAR2 (E488Q), and AAV8-CRISPR). Partial restoration of 
nNOS localization is also seen in treated samples (scale bar: 250μm). (c) In vivo TAA-
>TGG/TAG/TGA RNA editing efficiencies in corresponding treated adult mdx mice. Values 
represent mean +/− SEM (n=4, 3, 7, 3, 3, 10, 3, 4 independent TA muscles respectively). (d) 
Schematic of the OTC locus in the spfash mouse model of Ornithine Transcarbamylase 
deficiency which have a G->A point mutation at a donor splice site in the last nucleotide of 
exon 4, and approach for correction of mutant OTC mRNA via ADAR2 mediated RNA 
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editing. (e) In vivo RNA correction efficiencies in the correctly spliced OTC mRNA in the 
livers of treated adult spfash mice (retro-orbital injections of AAV8-ADAR2 and AAV8-
ADAR2 (E488Q)). Values represent mean +/− SEM (n=4, 4, 3, 3, 4, 5 independent animals 
respectively).
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